Two-component Radiology-guided Autonomous Cascade Engine (TRACE)
NCT07651644
Summary
This study employed a prospective, randomised crossover trial design to evaluate the clinical utility of the TRACE artificial intelligence system for gastric cancer T-staging. A total of 54 radiologists from tertiary and non-tertiary hospitals, including both senior and junior practitioners, were enrolled. The study aimed to investigate whether AI-assisted diagnosis could improve the diagnostic accuracy of gastric cancer T-staging compared with independent interpretation by radiologists. All participants were required to interpret 60 contrast-enhanced CT cases sequentially, completing two readings for each case: one without AI assistance and one with AI assistance; The order of the two readings was randomised, and a one-month washout period was observed between readings to eliminate memory bias. All cases were pathologically confirmed gastric cancer cases (stages T1-T4b), and the study simultaneously recorded the physicians' T-staging diagnostic results and the time taken per case. The 60 cases per radiologist were randomly selected from a pool of 1,000 histologically confirmed gastric cancer cases, stratified by pathological T stage T1-T4b. The reference standard was postoperative pathological T stage. The primary outcome was the change in T-staging accuracy between AI-assisted reading and standard (unaided) reading.The term "prospective" in this study refers to the prospective execution of radiologist enrollment, randomization, reading procedures, and data collection.
Eligibility
Inclusion Criteria (Imaging Data) 1. Contrast-enhanced CT (CE-CT) images of gastric cancer patients from the Liaoning Cancer Hospital; 2. Patients with a definitive postoperative pathological diagnosis of gastric cancer and a clear T-stage classification (T1-T4, including T4a and T4b); 3. Imaging data must be complete and of sufficient quality to meet diagnostic and analytical requirements, with no significant artefacts or missing key data; 4. Complete clinical and pathological information must be available to establish a diagnostic gold standard for comparison. Physician Inclusion Criteria (Image Readers) 1. Radiologists holding a valid medical licence; 2. From the radiology department of a Grade A tertiary hospital or a non-Grade A tertiary hospital; 3. Classified as senior or junior physicians based on clinical experience; 4. Voluntarily participating in this study and completing both the non-AI-assisted and AI-assisted image interpretation tasks. Case Exclusion Criteria 1. Severe missing imaging data or quality failing to meet analysis requirements (e.g., severe motion artefacts); 2. Lack of clear postoperative pathological T-staging results; 3. Cases not involving gastric cancer or with incomplete pathological information; 4. Cases of duplicate enrolment or inconsistent data recording. Physician Exclusion Criteria 1. Those unable to complete all image review tasks or demonstrating severe non-compliance; 2. Those who withdraw during the study period and are unable to provide complete data for both phases of image review; 3. Those who fail to complete the AI-assisted and non-AI-assisted interpretation processes as specified. Withdrawal Criteria 1. Physicians who voluntarily withdraw from the study for personal reasons (e.g., time, health or work commitments); 2. Physicians who fail to complete the required image review tasks or have data missing in excess of the specified threshold; 3. Cases where critical data errors are identified during subsequent verification or where pathological results cannot be traced; Data found during the study to be non-compliant with ethical or quality control requirements must be excluded.
Conditions2
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07651644